Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)
Center for Outcomes Research
Health Services Research | Musculoskeletal Diseases | Women's Health
Antiosteoporosis medication (AOM) does not abolish fracture risk, and some individuals experience multiple fractures while on treatment. Therefore, criteria for treatment failure have recently been defined. Using data from the Global Longitudinal Study of Osteoporosis in Women (GLOW), we analyzed risk factors for treatment failure, defined as sustaining two or more fractures while on AOM. GLOW is a prospective, observational cohort study of women aged ≥55 years sampled from primary care practices in 10 countries. Self-administered questionnaires collected data on patient characteristics, fracture risk factors, previous fractures, AOM use, and health status. Data were analyzed from women who used the same class of AOM continuously over 3 survey years and had data available on fracture occurrence. Multivariable logistic regression was used to identify independent predictors of treatment failure. Data from 26,918 women were available, of whom 5550 were on AOM. During follow-up, 73 of 5550 women in the AOM group (1.3%) and 123 of 21,368 in the non-AOM group (0.6%) reported occurrence of two or more fractures. The following variables were associated with treatment failure: lower Short Form 36 Health Survey (SF-36) score (physical function and vitality) at baseline, higher Fracture Risk Assessment Tool (FRAX) score, falls in the past 12 months, selected comorbid conditions, prior fracture, current use of glucocorticoids, need of arms to assist to standing, and unexplained weight loss ≥10 lb (≥4.5 kg). Three variables remained predictive of treatment failure after multivariable analysis: worse SF-36 vitality score (odds ratio [OR] per 10-point increase, 0.85; 95% confidence interval [CI], 0.76-0.95; p = 0.004); two or more falls in the past year (OR, 2.40; 95% CI, 1.34-4.29; p = 0.011), and prior fracture (OR, 2.93; 95% CI, 1.81-4.75; p < 0.0001). The C statistic for the model was 0.712. Specific strategies for fracture prevention should therefore be developed for this subgroup of patients. © 2014 American Society for Bone and Mineral Research.
Antiresorptive therapy, Osteoporosis treatment, Risk factors, Treatment failure
DOI of Published Version
Díez-Pérez A, Adachi JD, Adami S, Anderson FA Jr, Boonen S, Chapurlat R, Compston JE, Cooper C, Gehlbach SH, Greenspan SL, Hooven FH, Lacroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Siris ES, Wyman A, Rushton-Smith SK, Watts NB; Global Longitudinal Study of Osteoporosis in Women (GLOW) Investigators. Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW). J Bone Miner Res. 2014 Jan;29(1):260-7. doi: 10.1002/jbmr.2023. Link to article on publisher's website
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Diez-Perez, Adolfo; Adachi, Jonathan D.; Adami, Silvano; Anderson, Frederick A. Jr.; Boonen, Steven; Roland D.; Compston, Juliet E.; Cooper, Cyrus; Gehlbach, Stephen H.; Greenspan, Susan L.; Hooven, Fred H.; LaCroix, Andrea Z.; Nieves, Jeri W.; Netelenbos, J. Coen; Pfeilschifter, Johannes; Rossini, Maurizio; Roux, Christian; Saag, Kenneth G.; Silverman, Stuart; Siris, Ethel S.; Wyman, Allison; Rushton-Smith, Sophie; Watts, Nelson B.; and Global Longitudinal Study of Osteoporosis in Women (GLOW) Investigators, "Risk Factors for Treatment Failure With Antiosteoporosis Medication: The Global Longitudinal Study of Osteoporosis in Women (GLOW)" (2014). GLOW Publications. 19.